Jan 26 (Reuters) - Seattle Genetics:
* Seattle genetics inc /wa
* Says sgn-35, an antibody-drug conjugate, has been granted orphan drug
designation by FDA for the treatment of anaplastic large cell lymphoma
* Says sgn-35 granted orphan drug designation by European medicines agency for
the treatment of hodgkin lymphoma and anaplastic large cell lymphoma
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Seattle Genetics click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Seattle genetics inc /wa
* Says sgn-35, an antibody-drug conjugate, has been granted orphan drug
designation by FDA for the treatment of anaplastic large cell lymphoma
* Says sgn-35 granted orphan drug designation by European medicines agency for
the treatment of hodgkin lymphoma and anaplastic large cell lymphoma
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Seattle Genetics click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.